Floatz logo

ML261

Prostate Neuroendocrine Neoplasm

Moonlight Bio, IncCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Prostate Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Tarlatamab
Inkeun Park
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 34 →

Same molecule, other indications

ML261 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Dormant
CC
Indicative ·
43 / 100
View asset →
Gastroenteropancreatic NEC (GEP NEC)Dormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →